News - Vascepa

Filter

Current filters:

Vascepa

Popular Filters

Amarin files suit against AstraZeneca over Epanova

Amarin files suit against AstraZeneca over Epanova

05-03-2014

US biotech firm Amarin revealed in a Stock Exchange Commission submission that it has filed a complaint…

AmarinAstraZenecaBiotechnologyCardio-vascularEpanovaLegalNorth AmericaOmthera PharmaceuticalsPatentsUSAVascepa

Amarin calls on FDA to extend Vascepa exclusivity by five years

28-02-2014

US biotech firm Amarin has filed with a federal court requesting it to order the US Food and Drug Administration…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLegalLovazaNorth AmericaUSAVascepa

Amarin cuts 50% of staff after negative FDA decision

23-10-2013

Amarin has announced plans to cut 50% of its staff worldwide after the recent US Food and Drug Administration…

AmarinCardio-vascularFinancialManagementNorth AmericaPharmaceuticalVascepa

FDA advisory panel goes negative on Amarin’s Vascepa

FDA advisory panel goes negative on Amarin’s Vascepa

17-10-2013

US biotech firm Amarin revealed yesterday that the US Food and Drug Administration Endocrinologic and…

AmarinBiotechnologyCardio-vascularNorth AmericaRegulationVascepa

US FDA clears Amarin's Vascepa, a competitor for Lovaza

30-07-2012

The US Food and Drug Administration has approved biotech firm Amarin's (Nasdaq: AMRN) Vascepa (icosapent…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLovazaMergers & AcquisitionsNorth AmericaRegulationVascepa

Back to top